16 result(s) have been found!
| Accession | Name | Sequence | Source/Organism | Mechanism | Assay Type | Cell Line | Cancer Type | Activity |
|---|---|---|---|---|---|---|---|---|
| dbacp03578 | L17A/L21A | KWKSFLKTFKSAKKTVAHTAAKAISS | PeptideV13K | Membrane disruption mechanism | MTT/MTS assay | A-549 | Lung cancer | IC50 : > 83.6 µMo/L |
| dbacp03579 | L17A/L21A | KWKSFLKTFKSAKKTVAHTAAKAISS | PeptideV13K | Membrane disruption mechanism | MTT/MTS assay | A-375 | Skin cancer | IC50 : > 83.6 µMo/L |
| dbacp03580 | L17A/L21A | KWKSFLKTFKSAKKTVAHTAAKAISS | PeptideV13K | Membrane disruption mechanism | MTT/MTS assay | MCF-7 | Breast cancer | IC50 : > 83.6 µMo/L |
| dbacp03581 | L17A/L21A | KWKSFLKTFKSAKKTVAHTAAKAISS | PeptideV13K | Membrane disruption mechanism | MTT/MTS assay | SW-1116 | Colorectal cancer | IC50 : > 83.6 µMo/L |
| dbacp03582 | L17A/L21A | KWKSFLKTFKSAKKTVAHTAAKAISS | PeptideV13K | Membrane disruption mechanism | MTT/MTS assay | RD | Rhabdomyosarcoma cancer | IC50 : > 83.6 µMo/L |
| dbacp03583 | L17A/L21A | KWKSFLKTFKSAKKTVAHTAAKAISS | PeptideV13K | Membrane disruption mechanism | MTT/MTS assay | H-1299 | Lung cancer | IC50 : 37.7 µMo/L |
| dbacp03584 | L17A/L21A | KWKSFLKTFKSAKKTVAHTAAKAISS | PeptideV13K | Membrane disruption mechanism | MTT/MTS assay | B-16 | Skin cancer | IC50 : >83.6 µMo/L |
| dbacp03585 | L17A/L21A | KWKSFLKTFKSAKKTVAHTAAKAISS | PeptideV13K | Membrane disruption mechanism | MTT/MTS assay | HeLa | Cervical cancer | IC50 : >83.6 µMo/L |
| dbacp03589 | L21A | KWKSFLKTFKSAKKTVAHTAAKAISS | PeptideV13K | Membrane disruption mechanism | MTT/MTS assay | A-549 | Lung cancer | IC50 : 71 µMo/L |
| dbacp03590 | L21A | KWKSFLKTFKSAKKTVAHTAAKAISS | PeptideV13K | Membrane disruption mechanism | MTT/MTS assay | A-375 | Skin cancer | IC50 : 59.8 µMo/L |
| dbacp03591 | L21A | KWKSFLKTFKSAKKTVAHTAAKAISS | PeptideV13K | Membrane disruption mechanism | MTT/MTS assay | MCF-7 | Breast cancer | IC50 : 70.8 µMo/L |
| dbacp03592 | L21A | KWKSFLKTFKSAKKTVAHTAAKAISS | PeptideV13K | Membrane disruption mechanism | MTT/MTS assay | SW-1116 | Colorectal cancer | IC50 : >83.6 µMo/L |
| dbacp03593 | L21A | KWKSFLKTFKSAKKTVAHTAAKAISS | PeptideV13K | Membrane disruption mechanism | MTT/MTS assay | RD | Rhabdomyosarcoma cancer | IC50 : >83.6 µMo/L |
| dbacp03594 | L21A | KWKSFLKTFKSAKKTVAHTAAKAISS | PeptideV13K | Membrane disruption mechanism | MTT/MTS assay | H-1299 | Lung cancer | IC50 : 15.6 µMo/L |
| dbacp03595 | L21A | KWKSFLKTFKSAKKTVAHTAAKAISS | PeptideV13K | Membrane disruption mechanism | MTT/MTS assay | B-16 | Skin cancer | IC50 : 63.5 µMo/L |
| dbacp03596 | L21A | KWKSFLKTFKSAKKTVAHTAAKAISS | PeptideV13K | Membrane disruption mechanism | MTT/MTS assay | HeLa | Cervical cancer | IC50 : 64.7 µMo/L |